IN2014CN04067A - - Google Patents
Download PDFInfo
- Publication number
- IN2014CN04067A IN2014CN04067A IN4067CHN2014A IN2014CN04067A IN 2014CN04067 A IN2014CN04067 A IN 2014CN04067A IN 4067CHN2014 A IN4067CHN2014 A IN 4067CHN2014A IN 2014CN04067 A IN2014CN04067 A IN 2014CN04067A
- Authority
- IN
- India
- Prior art keywords
- cancer
- vegf
- met
- directed
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Quinoline Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161557358P | 2011-11-08 | 2011-11-08 | |
PCT/US2012/064116 WO2013070890A1 (en) | 2011-11-08 | 2012-11-08 | Dual inhibitor of met and vegf for treating cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2014CN04067A true IN2014CN04067A (ja) | 2015-10-23 |
Family
ID=47179011
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN4067CHN2014 IN2014CN04067A (ja) | 2011-11-08 | 2012-11-08 |
Country Status (15)
Country | Link |
---|---|
US (1) | US20140323522A1 (ja) |
EP (1) | EP2776033A1 (ja) |
JP (2) | JP2014532766A (ja) |
KR (1) | KR20140088610A (ja) |
CN (1) | CN104159585A (ja) |
AU (2) | AU2012335737A1 (ja) |
BR (1) | BR112014011009A2 (ja) |
CA (1) | CA2854336A1 (ja) |
EA (1) | EA201490944A1 (ja) |
HK (1) | HK1202062A1 (ja) |
IL (1) | IL232421A0 (ja) |
IN (1) | IN2014CN04067A (ja) |
MX (1) | MX2014005458A (ja) |
TW (2) | TWI662962B (ja) |
WO (1) | WO2013070890A1 (ja) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UA108618C2 (uk) | 2009-08-07 | 2015-05-25 | Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку | |
EP2621481B2 (en) | 2010-09-27 | 2022-10-19 | Exelixis, Inc. | Dual inhibitors of met and vegf for the treatment of castration-resistant prostate cancer and osteoblastic bone metastases |
KR20230158644A (ko) | 2011-02-10 | 2023-11-20 | 엑셀리시스, 인코포레이티드 | 퀴놀린 화합물들의 제조 방법들 및 상기 화합물들을 함유하는 약학 조성물들 |
US20120252840A1 (en) | 2011-04-04 | 2012-10-04 | Exelixis, Inc. | Method of Treating Cancer |
MX2013012695A (es) | 2011-05-02 | 2014-03-27 | Exelixis Inc | Metodo para el tratamiento del cancer y el dolor por cancer de hueso. |
BR112014006702A2 (pt) | 2011-09-22 | 2017-06-13 | Exelixis Inc | método para tratar osteoporose |
AU2012325768B2 (en) | 2011-10-20 | 2017-08-10 | Exelixis, Inc. | Process for preparing quinoline derivatives |
WO2013166296A1 (en) * | 2012-05-02 | 2013-11-07 | Exelixis, Inc. | A dual met - vegf modulator for treating osteolytic bone metastases |
ES2729626T3 (es) | 2013-03-15 | 2019-11-05 | Exelixis Inc | Metabolitos de N-(4-{[6,7-bis(metiloxi)quinolin-4-il]oxi}fenil)-N'-(4-fuorofenil)ciclopropano-1,1-dicarboxamida |
WO2014165786A1 (en) | 2013-04-04 | 2014-10-09 | Exelixis, Inc. | Cabozantinib dosage form and use in the treatment of cancer |
US9149471B2 (en) * | 2013-09-30 | 2015-10-06 | National University Corporation Tokyo University Of Agriculture And Technology | Therapeutic agent for osteoporosis |
JP6756617B2 (ja) | 2014-02-14 | 2020-09-16 | エグゼリクシス, インコーポレイテッド | N−{4−[(6,7−ジメトキシキノリン−4−イル)オキシ]フェニル}−n’−(4−フルオロフェニル)シクロプロパン−1,1−ジカルボキサミドの結晶性固体形態、製造プロセス、及び使用方法 |
JP6666849B2 (ja) | 2014-03-17 | 2020-03-18 | エグゼリクシス, インコーポレイテッド | カボザンチニブ製剤の投与 |
CN104788372B (zh) * | 2014-07-25 | 2018-01-30 | 上海圣考医药科技有限公司 | 一种氘代卡博替尼衍生物、其制备方法、应用及其中间体 |
JP6789923B2 (ja) | 2014-07-31 | 2020-11-25 | エグゼリクシス, インコーポレイテッド | フッ素18標識化カボザンチニブ及びその類似体の調製方法 |
MA40457A (fr) | 2014-08-05 | 2017-06-14 | Exelixis Inc | Combinaison de médicaments pour traiter le myélome multiple |
CN105503717A (zh) * | 2014-09-24 | 2016-04-20 | 江苏奥赛康药业股份有限公司 | 一种苹果酸卡博替尼化合物及其药物组合物 |
CN109069499A (zh) * | 2016-04-15 | 2018-12-21 | 埃克塞里艾克西斯公司 | 使用 n-(4-(6,7-二甲氧基喹啉-4-基氧基)苯基)-n’-(4-氟苯基)环丙烷-1,1-二甲酰胺,(2s)-羟基丁二酸盐治疗肾细胞癌的方法 |
WO2018072614A1 (zh) * | 2016-10-18 | 2018-04-26 | 北京康辰药业股份有限公司 | 一种喹啉基取代的羧酸化合物或其药学上可接受的盐、其药物组合物及应用 |
CN110621662B (zh) | 2017-05-26 | 2023-06-23 | 埃克塞里艾克西斯公司 | 一种盐的结晶性固体形式、制备工艺和使用方法 |
KR20200115582A (ko) | 2018-01-26 | 2020-10-07 | 엑셀리시스, 인코포레이티드 | 키나제-의존성 장애의 치료용 화합물 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4107288A (en) | 1974-09-18 | 1978-08-15 | Pharmaceutical Society Of Victoria | Injectable compositions, nanoparticles useful therein, and process of manufacturing same |
US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
SI2213661T1 (sl) | 2003-09-26 | 2011-11-30 | Exelixis Inc | c-Met modulatorji in postopki uporabe |
US20080200515A1 (en) | 2006-12-29 | 2008-08-21 | Tap Pharmaceutical Products Inc. | Solid state forms of enantiopure ilaprazole |
UA108618C2 (uk) * | 2009-08-07 | 2015-05-25 | Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку | |
CN103391773A (zh) * | 2010-09-27 | 2013-11-13 | 埃克塞里艾克西斯公司 | 用于治疗去势抵抗性前列腺癌和成骨性骨转移的met和vegf的双重抑制剂 |
EP2621481B2 (en) * | 2010-09-27 | 2022-10-19 | Exelixis, Inc. | Dual inhibitors of met and vegf for the treatment of castration-resistant prostate cancer and osteoblastic bone metastases |
-
2012
- 2012-11-08 JP JP2014541256A patent/JP2014532766A/ja active Pending
- 2012-11-08 KR KR1020147015127A patent/KR20140088610A/ko not_active Application Discontinuation
- 2012-11-08 EA EA201490944A patent/EA201490944A1/ru unknown
- 2012-11-08 EP EP12787328.9A patent/EP2776033A1/en not_active Ceased
- 2012-11-08 IN IN4067CHN2014 patent/IN2014CN04067A/en unknown
- 2012-11-08 CN CN201280066410.5A patent/CN104159585A/zh active Pending
- 2012-11-08 BR BR112014011009A patent/BR112014011009A2/pt not_active IP Right Cessation
- 2012-11-08 AU AU2012335737A patent/AU2012335737A1/en not_active Abandoned
- 2012-11-08 WO PCT/US2012/064116 patent/WO2013070890A1/en active Application Filing
- 2012-11-08 MX MX2014005458A patent/MX2014005458A/es unknown
- 2012-11-08 US US14/356,927 patent/US20140323522A1/en not_active Abandoned
- 2012-11-08 TW TW101141696A patent/TWI662962B/zh active
- 2012-11-08 TW TW106131943A patent/TW201818937A/zh unknown
- 2012-11-08 CA CA2854336A patent/CA2854336A1/en not_active Abandoned
-
2014
- 2014-05-01 IL IL232421A patent/IL232421A0/en unknown
-
2015
- 2015-03-13 HK HK15102604.7A patent/HK1202062A1/xx unknown
-
2017
- 2017-09-08 AU AU2017225103A patent/AU2017225103A1/en not_active Abandoned
- 2017-10-04 JP JP2017193945A patent/JP2018048154A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2014532766A (ja) | 2014-12-08 |
EP2776033A1 (en) | 2014-09-17 |
TWI662962B (zh) | 2019-06-21 |
CA2854336A1 (en) | 2013-05-16 |
AU2017225103A1 (en) | 2017-09-28 |
WO2013070890A1 (en) | 2013-05-16 |
HK1202062A1 (en) | 2015-09-18 |
CN104159585A (zh) | 2014-11-19 |
JP2018048154A (ja) | 2018-03-29 |
BR112014011009A2 (pt) | 2017-06-06 |
IL232421A0 (en) | 2014-06-30 |
TW201322981A (zh) | 2013-06-16 |
US20140323522A1 (en) | 2014-10-30 |
AU2012335737A1 (en) | 2014-06-05 |
TW201818937A (zh) | 2018-06-01 |
MX2014005458A (es) | 2015-04-16 |
KR20140088610A (ko) | 2014-07-10 |
EA201490944A1 (ru) | 2014-10-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IN2014CN04067A (ja) | ||
MX2013003594A (es) | Inhibidores dobles de met y factor de crecimiento endotelial vascular (vegf) para el tratamiento de cancer de prostata resistente a la castracion y metastasis de osteoblasticas en los huesosl. | |
HK1202253A1 (en) | Combination treatment of cancer | |
IL304337A (en) | Antiandrogens for the treatment of castration-resistant prostate cancer without metastases | |
SG10201508495VA (en) | Combination treatment of cancer | |
BR112013024211A2 (pt) | tratamento de tumores sólidos | |
MX2011011431A (es) | Composicion para el tratamiento de cancer de prostata. | |
IL225689A0 (en) | Cancer treatment/inhibition of metastasis | |
ZA201300762B (en) | Novel combination therapy for the treatment of cancer | |
IL228430A0 (en) | Cancer treatment | |
IN2014DN00254A (ja) | ||
MX2013006526A (es) | Dosis de los derivados de arilsulfonamida. | |
GB201017316D0 (en) | Treatment of cancer/inhibition of metastasis | |
GB201121791D0 (en) | Combination treatment of cancer | |
GB201017356D0 (en) | Combination treatment of cancer | |
GB201017354D0 (en) | Treatment of cancer | |
JO3550B1 (ar) | مركب لمعالجة سرطان البروستاتا | |
GB201121783D0 (en) | Treatment of cancer | |
TH0901005197A (th) | การบำบัดต้านการเจริญเติบโตของเส้นโลหิตสำหรับการรักษาของโรคมะเร็งเต้านม |